Diagnostic Makers Seek Clarification On Biomarker Validation Standards
This article was originally published in The Gray Sheet
Executive Summary
FDA should elucidate biomarker terminology in finalizing its guidance on pharmacogenomic data submissions, Genzyme says in comments to the agency